Mizuho Medy Co Ltd operates within the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mizuho Medy Co Ltd with three other
pharmaceutical manufacturers in Asia:
Apex Biotechnology Corporation
sales of 2.04 billion Taiwanese Dollars [US$66.32 million]
(2.01 billion Taiwanese Dollars [US$65.13 million]
of which 100%
was Medical Department), and
BioSino Bio-technology and Science Inc
based in China
(303.22 million Chinese Renmimbi [US$45.23 million]
During the year ended December of 2018, sales at
Mizuho Medy Co Ltd were ¥6.42 billion (US$57.36 million).
increase of 14.2%
versus 2017, when the company's sales were ¥5.62 billion.
This was the fifth consecutive year of sales increases at Mizuho Medy Co Ltd
(and since 2013, sales have increased a total of 98%).